Clinical Trial Update: A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial of a triple-targeted CD19/CD20/CD22 CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Triple-targeted CD19/CD20/CD22 CAR-T cell therapy

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Lymphocytic Leukemia | Phase 1 | Status: TERMINATED